CytomX lays off 40% of staff, questions future of Amgen-partnered T-cell engager

CytomX Therapeutics is shrinking its head count by 40% as the biotech regroups and looks at fresh ways to conserve cash.

In order to focus its resources on its lead antibody-drug conjugate (ADC) and an array of Big Pharma partnerships, CytomX is considering the future of the Amgen-partnered CX-904, the company said in a Jan. 6 press release.